Evaluation Of The Efficacy Of Targeted Combination With Immunocheckpoint Inhibitors In The Treatment Of Advanced Renal Cell Carcinoma

Objective:The purpose of this study was to investigate the efficacy and safety of targeted combined immune checkpoint inhibitors in the treatment of advanced renal cancer using data from actual patients treated at our institution.Methods:Between February 2020 and February 2023,15 patients with advanced renal cell carcinoma were admitted to the First Affiliated Hospital of Xinjiang Medical University for treatment with targeted combination immune checkpoint inhibitors.Effectiveness and frequency of side effects were assessed at least once every two cycles during the course of combination therapy.Results:The median follow-up time was 7.0 months(range 1.2-12.4).For the purpose of assessing efficacy,11 patients were in partial remission,2 patients had stable disease and 1 patient was progressing.The objective remission rate for patients with advanced renal cancer was 73.3%(11/15)and the disease control rate was 93.3%(14/15).Median overall survival(mOS)and progression-free survival(mPFS)could not be calculated due to the limited follow-up time.Overall,the incidence of adverse events was 80.0%(12/15),with a rate of 80.0%(12/15)for grade 1/2 adverse reactions and 13.3%(2/15)for grade 3/4 adverse reactions.There were no deaths of any grade.Loss of appetite,nausea,vomiting and diarrhoea(3/17)and skin reactions(pruritus,rash,etc.)(6/15)were the most commonly reported adverse events,while gingivitis,thrombocytopenia and elevated transaminases each affected one patient.No cases of nephrotoxicity,immune pneumonia,osteoarthritis,myotoxicity or any other unusual toxicity were identified in this cohort.Due to the low frequency of serious adverse reactions and manageable side effects.Conclusion:T The combination of targeted agents with immune checkpoint PD-1/PD-L1 inhibitors is effective and safe in the treatment of advanced kidney cancer.